News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
126,330 Results
Type
Article (4290)
Company Profile (94)
Press Release (121946)
Section
Business (42105)
Career Advice (207)
Deals (6157)
Drug Delivery (13)
Drug Development (17414)
Employer Resources (18)
FDA (1487)
Job Trends (2775)
News (66218)
Policy (3643)
Tag
Academia (288)
Alliances (11392)
Alzheimer's disease (269)
Approvals (1475)
Artificial intelligence (29)
Bankruptcy (37)
Best Places to Work (2225)
Biotechnology (89)
Breast cancer (33)
Cancer (249)
Career advice (195)
CAR-T (21)
Cell therapy (86)
Clinical research (13550)
Collaboration (111)
Compensation (32)
COVID-19 (412)
C-suite (41)
Cystic fibrosis (17)
Data (269)
Diabetes (21)
Diagnostics (666)
Drug discovery (23)
Earnings (12116)
Employer resources (18)
Events (23895)
Executive appointments (101)
FDA (1576)
Funding (86)
Gene therapy (44)
GLP-1 (94)
Government (338)
Healthcare (1501)
Infectious disease (426)
Inflammatory bowel disease (36)
Interviews (17)
IPO (2880)
Job creations (665)
Job search strategy (184)
Layoffs (34)
Legal (633)
Manufacturing (47)
Medical device (393)
Medtech (393)
Mergers & acquisitions (3340)
Metabolic disorders (60)
Neuroscience (327)
NextGen Class of 2024 (853)
Non-profit (268)
Northern California (433)
Obesity (32)
Opinion (38)
Parkinson's disease (18)
Patents (25)
People (16044)
Phase I (5368)
Phase II (6461)
Phase III (3334)
Pipeline (112)
Policy (22)
Postmarket research (209)
Preclinical (2327)
Press Release (51)
Radiopharmaceuticals (44)
Rare diseases (37)
Real estate (1438)
Regulatory (2829)
Research institute (296)
Resumes & cover letters (20)
Southern California (404)
Startups (987)
United States (3413)
Vaccines (51)
Weight loss (17)
Date
Today (53)
Last 7 days (274)
Last 30 days (952)
Last 365 days (9118)
2024 (8208)
2023 (9915)
2022 (12030)
2021 (12665)
2020 (9876)
2019 (6687)
2018 (5295)
2017 (6083)
2016 (5596)
2015 (6439)
2014 (4927)
2013 (4062)
2012 (4402)
2011 (4871)
2010 (4514)
Location
Africa (135)
Alabama (19)
Asia (8339)
Australia (1945)
California (974)
Canada (334)
China (55)
Connecticut (32)
Europe (18034)
Florida (86)
Illinois (88)
Indiana (53)
Maryland (116)
Massachusetts (701)
Michigan (50)
Minnesota (63)
New Jersey (250)
New York (238)
North Carolina (173)
Northern California (433)
Ohio (26)
Pennsylvania (222)
South America (198)
Southern California (404)
Texas (93)
Washington State (215)
126,330 Results for "insilico biotechnology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Clinical research
Insilico Aces Second Mid-Stage IPF Trial in a Row
In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and was well-tolerated across all dosing groups.
November 12, 2024
·
2 min read
·
Heather McKenzie
Drug development
Boehringer, Insilico Appear to Break Through Against IPF
Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary fibrosis, an intractable lung disease for which current treatment options fail to stop progression, but the data were limited, leaving experts wanting.
September 24, 2024
·
4 min read
·
Heather McKenzie
GNQ Insilico’s AI-Driven Digital Twin Platform Shows Promising Results in First Virtually Simulated Clinical Drug Trial
Trenchant Technologies Capital (CSE: AITT) (OTC: AITTF) (FSE: 5730) “Trenchant” or “the Company”), is pleased to announce that its portfolio company GNQ Insilico (“GNQ”) has demonstrated promising results in synthesizing digital twins of human patients, and simulating the effects of an infertility drug on these digital replicas using its proprietary AI-driven platform.
June 18, 2024
·
6 min read
In-silico Drug Discovery Market to Reach USD 40.3 Billion to 2031 with a CAGR of 18.05% from 2024
“In-silico Drug Discovery Market” in terms of revenue was estimated to be worth $10.9 Bn in 2023 and is poised to reach $40.3 Bn by 2031, growing at a CAGR of 18.05% from 2024 to 2031 according to a new report by InsightAce Analytic.
April 30, 2024
·
6 min read
Press Releases
AI for Good: Insilico Medicine Hosts IMGAIA Product Launch Event
July 24, 2024
·
3 min read
Insilico CEO Alex Zhavoronkov Discusses AI Drug Discovery
The CEO of Insilico Medicine, which recently became the first company to launch Phase II trials for a drug developed using generative AI, spoke with BioSpace about the rise of the technology.
January 17, 2024
·
3 min read
·
Tyler Patchen
Press Releases
Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI
September 18, 2024
·
7 min read
Drug Development
Launch of Insilico’s Phase II Program Highlights Generative AI Momentum
Insilico’s AI platform has attracted interest from a growing number of biopharma companies. Meanwhile, several other firms highlight their own AI technologies.
August 11, 2023
·
5 min read
·
Ana Mulero
Pharm Country
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications
The Menarini Group and Stemline Therapeutics, Inc. announced that they have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico’s AI platform, as a potential treatment for hormone sensitive cancers and other oncology indications.
January 4, 2024
·
6 min read
Business
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
Exelixis, Inc. and Insilico Medicine (“Insilico”) today announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors.
September 12, 2023
·
7 min read
1 of 12,633
Next